🇺🇸 FDA
Pipeline program

A Phase 1 first-in-human study to evaluate SAR447754 in healthy adult participants and in adult participants with moderate-to-severe atopic dermatitis.

SAD18615-MAD18616

Phase 1 other active

Quick answer

A Phase 1 first-in-human study to evaluate SAR447754 in healthy adult participants and in adult participants with moderate-to-severe atopic dermatitis. for Dermatitis atopic is a Phase 1 program (other) at Sanofi Pharma Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).

Program details

Company
Sanofi Pharma Bristol-Myers Squibb
Indication
Dermatitis atopic
Phase
Phase 1
Modality
other
Status
active

Clinical trials